Pharmaxis (Pharmaxis) Other Net Income (Loss) : $1.23 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Pharmaxis Other Net Income (Loss)?

Pharmaxis's Other Net Income (Loss) for the six months ended in Dec. 2023 was $1.23 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.23 Mil.

Pharmaxis's quarterly Other Net Income (Loss) stayed the same from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($0.00 Mil) but then increased from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($1.23 Mil).

Pharmaxis Other Net Income (Loss) Historical Data

The historical data trend for Pharmaxis's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaxis Other Net Income (Loss) Chart

Pharmaxis Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Other Net Income (Loss)

Get a 7-Day Free Trial

Pharmaxis Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	1.23

Pharmaxis Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.23 Mil.

Pharmaxis Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Pharmaxis's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaxis (Pharmaxis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmaxis Ltd (OTCPK:PXSLY) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

UUDA:Germany SNT:Australia

Address

20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.pharmaxis.com.au

Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.

Pharmaxis (Pharmaxis) Headlines

From GuruFocus

FDA Bronchitol Approval to Generate Cash Flows for Pharmaxis

By Business Wire Business Wire • 11-02-2020

Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial

By PRNewswire PRNewswire • 08-31-2021

Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial

By PRNewswire PRNewswire • 08-04-2021

Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model

By PRNewswire PRNewswire • 08-05-2021

FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer

By PRNewswire PRNewswire • 11-09-2021

Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial

By PRNewswire PRNewswire • 10-05-2021